Barclays raises Insulet stock price target following robust Q3 beat By Investing.com
On Monday (NASDAQ:), Barclays (LON:) analyst increased the price target for Insulet (NASDAQ:) Corporation (NASDAQ:PODD) to $234 from $220, while maintaining an Equal-weight rating on the stock. The adjustment follows Insulet’s third-quarter performance, which surpassed analyst estimates and Bloomberg consensus, mainly due to growth in international sales and drug delivery revenues.
The company reported a significant increase in sales, particularly from its international segment, which saw an addition of $19 million, and its drug delivery business, which contributed an extra $7 million. Insulet’s stock price responded positively to the strong quarterly results.
The analyst noted that the company is actively preparing for the…
